Equities Analysts Set Expectations for RDY Q2 Earnings

Posted by Brian Himes on Aug 11th, 2026

Dr. Reddy’s Laboratories Ltd (NYSE:RDY – Free Report) – Analysts at Zacks Research dropped their Q2 2027 earnings estimates for shares of Dr. Reddy’s Laboratories in a report issued on Monday, August 10th. Zacks Research analyst Team now expects that the company will post earnings per share of $0.16 for the quarter, down from their previous forecast of $0.17. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.47 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ FY2027 earnings at $0.43 EPS, Q1 2028 earnings at $0.11 EPS, Q2 2028 earnings at $0.14 EPS, Q3 2028 earnings at $0.13 EPS, Q4 2028 earnings at $0.11 EPS, FY2028 earnings at $0.50 EPS, Q1 2029 earnings at $0.14 EPS and FY2029 earnings at $0.61 EPS.

A number of other brokerages have also commented on RDY. Weiss Ratings lowered shares of Dr. Reddy’s Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Wall Street Zen downgraded Dr. Reddy’s Laboratories from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Finally, The Goldman Sachs Group downgraded shares of Dr. Reddy’s Laboratories from a “neutral” rating to a “sell” rating in a research note on Thursday, April 23rd. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Dr. Reddy’s Laboratories presently has a consensus rating of “Reduce”.

View Our Latest Stock Analysis on Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Stock Down 0.7%

NYSE:RDY opened at $12.14 on Tuesday. The company has a quick ratio of 1.39, a current ratio of 1.90 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $10.13 billion, a P/E ratio of 27.59, a P/E/G ratio of 2.45 and a beta of 0.29. The stock’s fifty day simple moving average is $13.14 and its 200-day simple moving average is $13.53. Dr. Reddy’s Laboratories has a 12-month low of $11.36 and a 12-month high of $15.67.

Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The company had revenue of $850.26 million during the quarter, compared to the consensus estimate of $850.56 million. Dr. Reddy’s Laboratories had a net margin of 10.15% and a return on equity of 9.49%.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

Large investors have recently made changes to their positions in the business. Rockefeller Capital Management L.P. lifted its position in shares of Dr. Reddy’s Laboratories by 67.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 2,047 shares of the company’s stock valued at $29,000 after buying an additional 821 shares during the last quarter. Russell Investments Group Ltd. grew its position in Dr. Reddy’s Laboratories by 803.8% in the fourth quarter. Russell Investments Group Ltd. now owns 3,091 shares of the company’s stock worth $43,000 after acquiring an additional 2,749 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in Dr. Reddy’s Laboratories by 71.7% during the second quarter. EverSource Wealth Advisors LLC now owns 3,100 shares of the company’s stock valued at $47,000 after purchasing an additional 1,294 shares in the last quarter. Larson Financial Group LLC raised its holdings in shares of Dr. Reddy’s Laboratories by 81.5% during the 4th quarter. Larson Financial Group LLC now owns 3,173 shares of the company’s stock valued at $45,000 after buying an additional 1,425 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Dr. Reddy’s Laboratories in the second quarter worth $67,000. 3.85% of the stock is owned by hedge funds and other institutional investors.

About Dr. Reddy’s Laboratories

(Get Free Report)

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.